Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study

Table 3 Standardized incidence ratios of subsequent breast-ACC among two-month female survivors of other first primary cancers

	First primary cancer		Subsequent breast-ACC
Site	n	Mean person-years	Obs.	SIR	95% CI
All, excluding nonmelanoma skin	1,239,815	7.04	20	0.86	0.52 to 1.33
All solid	1,122,676	7.24	20	0.91	0.56 to 1.41
Colon and rectum	151,082	6.42	5	1.70	0.55 to 3.96
Melanoma, skin	43,155	9.93	2	2.19	0.27 to 7.91
Female breast	410,448	8.58	7	0.71	0.28 to 1.46
Uterine corpus	90,916	10.48	2	0.69	0.08 to 2.48
Urinary bladder	29,309	7.41	2	2.99	0.36 to 10.81
All lymphohematopoietic cancers	96,222	5.80	0	[E = 1.24]

Data from the nine cancer registry areas of the Surveillance, Epidemiology and End Results Program, 1977 to 2006. Except for the general category of all lymphohematopoietic cancers, the table is limited to cancers with >1 case of subsequent breast-ACC. Breast-ACC, adenoid cystic carcinoma of the breast; n, number of first primary cancers; Obs., observed number of subsequent breast-ACC; SIR, standardized incidence ratio; CI, confidence interval; E, expected number of subsequent breast-ACC.

ISSN: 1465-542X